Koninklijke Philips N.V.

Koninklijke Philips N.V.

24.92
CHF
-3.78
(-13.17%)
0.93EPS
Feb 01Next Earn
Koninklijke Philips N.V.
BX:PHIA
(BX Swiss)

Recent

price

24.92

P/E

ratio

- -

div

yld

1.42%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
EUR
21.53
20.02
21.77
21.91
21.22
16.65
17.23
17.38
17.82
17.24
17.66
17.57
18.73
19.16
19.32
18.82
18.53
Revenue per Share
1.39
-1.39
-0.03
1.16
0.41
0.62
1.43
1.62
1.07
1.17
1.21
3.4
-1.69
-0.49
-0.75
0.94
1
Basic EPS, GAAP
1.95
-0.03
1.81
0.86
1.18
0.49
1.06
1.72
1.63
1.68
2.45
1.56
-0.29
2.15
1.56
1.09
2.48
Free Cash Flow per Basic Share
0.29
0.25
0.25
0.27
0.29
0.3
0.33
0.38
0.39
0.46
- -
0.49
0.43
- -
- -
0.35
0.37
Dividend per Share
14.43
12.07
11.07
10.85
10.79
11.54
12.35
11.76
12
12.83
12.15
15.37
13.92
12.84
12.99
11.53
11.85
Book Value per Share
2.7
1.28
0.47
1.4
0.34
-0.55
0.09
0.93
- -
0.49
0.88
0.16
-0.54
-1.11
-1.47
-0.93
-0.72
Tangible Book Value per Share
1,035
1,048
1,021
1,004
1,008
1,009
1,011
1,023
1,017
995
980
976
952
948
933
948
958
Basic Weighted Avg Shares
22,287
20,992
22,234
21,990
21,391
16,806
17,421
17,780
18,121
17,147
17,312
17,156
17,827
18,169
18,021
17,834
17,756
Sales/Revenue/Turnover
9.31
4.17
2.66
8.56
2.29
3.92
8.42
7.99
9.13
8.11
8.11
3.63
-0.99
-0.92
2.85
8.12
8.91
Operating Margin (%)
1,343
1,400
1,242
1,177
1,187
972
976
1,025
1,089
1,343
1,462
1,323
1,602
1,261
1,389
1,124
1,178
Depreciation Expense
1,442
-1,460
-35
1,169
415
624
1,448
1,657
1,090
1,167
1,187
3,319
-1,608
-466
-702
895
957
Net Income, GAAP
25.45
- -
82.89
30.56
14.05
51.37
19.63
25.34
12.84
20.67
17.51
- -
- -
- -
782.93
23.86
27.95
Effective Tax Rate (%)
6.47
-6.96
-0.16
5.32
1.94
3.71
8.31
9.32
6.02
6.81
6.86
19.35
-9.02
-2.56
-3.9
5.02
5.39
Profit Margin (%)
3,839
3,109
2,573
2,998
3,715
2,734
3,602
3,252
1,629
2,481
3,493
2,898
2,325
1,654
1,878
2,421
2,599
Working Capital
2,818
3,278
3,725
3,309
3,712
4,095
4,021
3,468
3,238
4,876
5,590
5,737
7,017
6,959
7,048
6,811
6,985
LT Debt
15,092
12,350
11,185
11,227
10,968
11,780
13,453
12,023
12,117
12,625
11,901
14,475
13,283
12,061
12,043
10,989
11,609
Total Equity
7.92
- -
0.62
8.17
2.72
1.94
6.3
6.3
9.18
6.31
5.8
- -
- -
- -
-18.62
5.65
5.72
Return on Invested Capital (%)
8.72
- -
0.22
9.36
5.14
5.09
9.18
9.24
7.84
7.87
7.44
- -
- -
- -
-15.46
5.83
6.13
Return on Capital (%)
9.73
-10.67
-0.3
10.45
3.76
5.54
11.96
13.5
9.05
9.46
9.7
25.23
-11.62
-3.69
-5.84
7.8
8.65
Return on Common Equity (%)

Capital Structure

EUR

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1,206
1,149
1,154
LT Borrowings
6,891
6,316
6,985
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
951
977
977
Market Capitalization
- -
- -
- -

Working Capital

EUR

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
9,784
9,330
10,507
Cash, Cash Equivalents & STI
2,592
1,789
2,751
Accounts Receivable, Net
3,262
3,550
3,567
Inventories
3,110
3,216
3,404
Total Current Liabilities
7,432
7,423
7,908
Payables & Accruals
3,513
3,728
3,889
ST Debt
1,206
1,149
1,154
Deferred Revenue
1,617
1,584
1,635

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.19%
-0.94%
-8.75%
Free Cash Flow
-82.58%
-209.21%
-28.6%
Net Income, GAAP
-9.57%
-43.34%
-227.49%
Sales/Revenue/Turnover
0.63%
0.62%
-1.04%
Total Cash Common Dividend
8,058.07%
16,127.19%
32,700%

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,138
4,462
4,377
5,044
18,021
2025
4,097
4,338
4,302
5,098
17,834
2026
3,905
4,360
4,393
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.07
0.47
0.19
-0.36
-0.75
2025
0.08
0.25
0.19
0.42
0.94
2026
0.16
0.4
0.03
- -
- -

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
0.31
0.03
- -
0.35
2026
- -
0.34
0.04
- -
- -
Business
Koninklijke Philips N.V. functions as a global leader in health technology, dedicated to enhancing people's health and well-being through meaningful innovation across various international markets. The company structures its operations across key divisions: Diagnosis & Treatment, Connected Care, and Personal Health. Within its Diagnosis & Treatment segment, Philips provides advanced diagnostic imaging systems such as magnetic resonance (MRI), computed tomography (CT), X-ray, and ultrasound equipment, alongside integrated image-guided therapy solutions and enterprise diagnostic informatics for cardiology, radiology, and oncology. The Connected Care segment focuses on comprehensive patient monitoring solutions for hospitals and home settings, emergency care devices, and sleep and respiratory care products. Notably, the company has been actively addressing a significant voluntary recall issued in June 2021 concerning specific CPAP, BiPAP, and mechanical ventilator devices from its Respironics portfolio, working on remediation efforts for affected users globally. The Personal Health sector offers consumer-focused products, including innovative oral healthcare items like electric toothbrushes, mother and child care solutions, and male grooming and beauty appliances. Philips is deeply committed to digital transformation and artificial intelligence (AI) in healthcare, expanding strategic collaborations with partners like Amazon Web Services (AWS) to integrate cloud services and generative AI into diagnostic workflows. Recent innovations include AI-enhanced solutions for interventional cardiology, such as DeviceGuide, and expanded partnerships for AI-enabled neuroimaging. The company's business model emphasizes driving value through focused organic growth, patient-centric innovation, and a strong commitment to sustainability. Initially established in Eindhoven in 1891, Koninklijke Philips N.V. has evolved significantly, changing its name in May 2013 to reflect its sharpened focus on health technology. The multinational enterprise maintains its headquarters in Amsterdam, the Netherlands.

Company News

  • Here's Why You Should Retain PHG Stock in Your Portfolio for Now

  • Philips to nominate Dick Boer, Laurence Debroux and Todd Brinton to its Supervisory Board at the 2027 Annual General Meeting of Shareholders (AGM)

  • Philips Avent Launches New Natural Response Glass Baby Bottle with a Lighter, Stronger Design

  • Philips: 3 Key Takeaways for Long-Term Investors

  • What Koninklijke Philips (PHG) Said on Its Q3 Earnings Call

  • Philips Launches HyperVue Integrated System to Improve PCI Workflows

  • Philips Reports Strong Customer Demand, Improved Profitability

  • What Koninklijke Philips (PHG) Said on Its Q3 Earnings Call

  • Koninklijke Philips N.V. (PHG) Q3 2026 Earnings Call Transcript

  • Philips: The Recovery Is Real, But I Was Too Optimistic (Rating Downgrade)

  • Koninklijke Philips (NYSE:PHG) Share Price Breaks Above 200 Day Moving Average – Here’s What Happened

  • Philips Sales Rise Amid Product Recall Agreement

  • Philips beats quarterly profit estimates driven by higher sales, gross margin

  • Philips delivers strong order intake growth, comparable sales growth and strong margin expansion in Q3; 2026 outlook reiterated

  • Philips launches HyperVue Integrated System in the U.S., bringing advanced coronary imaging and physiology into the cathlab

  • Philips launches UniGuide 3D Live Guidance, bringing CT planning into live procedures and extending the capabilities of its Azurion image-guided therapy platform

  • Philips identifies three beauty tech trends set to transform beauty routines into lasting relationships by 2027

  • Gaming Has Become a Source of Real-World Style Inspiration. The Most Important Character That Gamers Are Customizing?

  • Philips highlights Integrated Diagnostics' role in the future of cardiovascular informatics following MediReport acquisition

  • Philips: A Risky Turnaround Worth A 'Strong Buy' Upgrade